Weight Loss, Diabetes, and Beyond
Pareek M, Schauer PR, Kaplan LM, et al.
J Am Coll Cardiol 2018;71(6)
Leggi
Blu
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study
Patorno E, Goldfine AB, Schneeweiss S, et al.
BMJ 2018;360:k119
Leggi
Hypertension and Diabetes Mellitus: Coprediction and Time Trajectories
Tsimihodimos V, Gonzalez-Villalpando C, Meigs JB, et al.
Hypertension 2018;71:422-8
Leggi
Cancer risk associated with chronic diseases and disease markers: prospective cohort study
Tu H, Wen CP, Tsai SP, et al.
BMJ 2018;360:k134
Leggi
Diabetes Mellitus and Right Ventricular Dysfunction in Heart Failure With Preserved Ejection Fraction
Thomas M. Gorter, Koen W. Streng, et al.
Am J Cardiol 2018;121:(5):621-7
Leggi
Empagliflozin across the stages of diabetic heart disease (Editorial)
Paneni F
Eur Heart J 2018; 39 (5): 371-3
Leggi
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME trial
Fitchett D, Butler J, van de Borne P, et al.
Eur Heart J 2018;39(5):363-70
Leggi
Age at Menarche and Incidence of Diabetes: A Prospective Study of 300,000 Women in China
Yang L, Li L, Peters SAE, et al.
Am J Epidemiol 2018;187(2):190-8
Leggi
Economic evaluation of type 2 diabetes prevention programmes: Markov model of low- and high-intensity lifestyle programmes and metformin in participants with different categories of intermediate hyperglycaemia
Roberts S, Craig D, Adler A, et al.
BMC Medicine. Pub. online 30 January 2018
Leggi
Built environmental characteristics and diabetes: a systematic review and meta-analysis
den Braver R, Lakerveld J, Rutters F, et al.
BMC Medicine. Pub. online 31 January 2018.
Leggi